UAE headquartered investment group Yas Holding has completed the acquisition of Gulf Inject LLC (GI) from Ras Al Khaimah-based Gulf Pharmaceutical Industries (Julphar), a listed UAE-based pharmaceutical company. The 100% acquisition, which includes Gulf Inject’s Jebel Ali Free Zone branch, was completed through Yas Holding’s dedicated healthcare investment vehicle, GlobalOne Healthcare Holding LLC (GHH).
GHH’s healthcare portfolio includes biopharma, manufacturing, medical supply chain, hospital and clinic management, healthcare technology, and occupational health and wellness.
The acquisition comes on the back of the UAE this week being announced as having the most competitive industrial sector in the Arab world, climbing five places to 30th in the world in the 2021 United Nations’ Industrial Organisation’s (UNIDO) Competitive Industrial Performance Index (CIP) report, which tracks 152 countries. The continuous improvement is in line with the UAE’s industrial strategy Operation 300bn, which aims to develop the country’s industrial sector and enhance its role in stimulating the national economy.
Founded in 1994, Gulf Inject manufactures and distributes sterile parenteral solutions and is a leading player in fluid management therapy in the UAE. From its well-established production facility in JAFZA Dubai, GI manufactures 65 products including injectables, IV infusions, antibiotics, local anaesthetics and hypertonic solutions which are used for the treatment of critical and chronically ill patients.
Suresh Vaidhyanathan, Group CFO of Yas Holding, said the acquisition seeks to generate several synergies that collectively position GHH as a premier healthcare investment company in the region.
According to Ashraf Radwan CEO of GlobalOne Healthcare, in combination with GHH’s Wellpharma Medical Solutions (WMS), this acquisition will see GHH assume a market leading position in the provision of domestic IV fluid, and among the top 3 regional players in the Middle East.
Across Gulf Inject and WMS the combined production capacity will exceed 28 million units of general intravenous fluids, electrolytes and injectable antibiotics, 20 million units of small volume sterile product formulations and 1.2 million units of large volume formulations including dialysis solutions.
Follow Arabian Post
Select Arabian Post as your preferred source on Google and MSN News for trusted business news and Arab politics and updates.
